ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Reproduction
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1639137
Associations between Serum 25-Hydroxyvitamin D Concentrations and Assisted Reproductive Technology Outcomes in Women with Polycystic Ovary Syndrome: A Cohort Study
Provisionally accepted- Guangdong Province Women and Children Hospital, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The impact of serum vitamin D levels on the success of assisted reproductive technology (ART) among women with polycystic ovary syndrome (PCOS) has not been fully explored. Methods: This cohort study enrolled 111 patients with PCOS who underwent in vitro fertilization (IVF) or intracyto-plasmic sperm injection (ICSI) treatment at Guangdong Women and Children Hospital from January 2022 to October 2024. Serum 25-hydroxyvitamin D [25(OH)D] concentrations were measured before embryo transfer (ET). The outcomes included the pregnancy rate, live birth rate, and early miscarriage rate. Multivariable logistic regression and the receiver operating characteristic (ROC) curve analyses were performed to evaluate predictive thresholds.Results: Patients achieving clinical pregnancy (n=76, 68.47%) exhibited significantly higher pre-ET 25(OH)D levels (65.28 ± 18.90 vs. 52.22 ± 15.14, nmol/L, P < 0.001) and luteinizing hormone (LH) levels (9.52 ± 6.37 vs. 6.94 ± 4.52, IU/L, P = 0.021) compared to non-pregnant counterparts. Logistic regression, after adjusting for LH, demographics and hormonal prodiles, revealed that 25(OH)D was significantly associated with pregnancy (B=0.13, P = 0.030). ROC analysis identified 67.95 nmol/L as the optimal 25(OH)D cutoff for predicting pregnancy (with an area under the curve of 0.703, a specificity of 94.3%, and a sensitivity of 36.8%). Furthermore, pregnancies with pre-ET 25(OH)D ≥67.95 nmol/L had significantly higher live birth rates (75.00% vs. 52.08%, P = 0.049). Live birth cases maintained higher 25(OH)D levels than early miscarriages (67.63±19.32 vs. 58.22±16.01, nmol/L, P = 0.042).Conclusions: Pre-ET serum vitamin D levels may serve as a modifiable biomarker for optimizing ART success in women with PCOS, associated with enhanced pregnancy likelihood and live birth outcomes. Systematic vitamin D supplementation prior to ET warrants further investigation as a potential adjuvant strategy.This study has been registered in the National Medical Research Registration and Filing Information System of China (MR-44-25-016940). Retrospectively registered on January 17, 2025.
Keywords: Polycystic Ovary Syndrome, Assisted Reproductive Technology, Vitamin D, Pregnancy, Live Birth
Received: 01 Jun 2025; Accepted: 26 Sep 2025.
Copyright: © 2025 Guo, Zheng, Gu, Zhang, Zhang, Ruan, Li, Mai, Wu and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mingyong Luo, luo-my@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.